ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2

Novo Nordisk has long been working on drugs that can help people earlier on in their diabetes and keep them from progressing to insulin treatment. But that doesn’t mean it’s not also working to improve the insulin options out there for those who do need it.

Sunday at the American Diabetes Association’s virtual annual meeting, the Danish drugmaker rolled out phase 2 results showing that insulin icodec—an up-and-coming insulin contender delivered just once per week—could match Sanofi’s once-daily giant Lantus in terms of blood sugar control and safety.